Literature DB >> 24101688

Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine.

Ediane B Silva1, Andrew Goodyear, Marjorie D Sutherland, Nicole L Podnecky, Mercedes Gonzalez-Juarrero, Herbert P Schweizer, Steven W Dow.   

Abstract

Infections with the Gram-negative bacterium Burkholderia pseudomallei (melioidosis) are associated with high mortality, and there is currently no approved vaccine to prevent the development of melioidosis in humans. Infected patients also do not develop protective immunity to reinfection, and some individuals will develop chronic, subclinical infections with B. pseudomallei. At present, our understanding of what constitutes effective protective immunity against B. pseudomallei infection remains incomplete. Therefore, we conducted a study to elucidate immune correlates of vaccine-induced protective immunity against acute B. pseudomallei infection. BALB/c and C57BL/6 mice were immunized subcutaneously with a highly attenuated, Select Agent-excluded purM deletion mutant of B. pseudomallei (strain Bp82) and then subjected to intranasal challenge with virulent B. pseudomallei strain 1026b. Immunization with Bp82 generated significant protection from challenge with B. pseudomallei, and protection was associated with a significant reduction in bacterial burden in lungs, liver, and spleen of immunized mice. Humoral immunity was critically important for vaccine-induced protection, as mice lacking B cells were not protected by immunization and serum from Bp82-vaccinated mice could transfer partial protection to nonvaccinated animals. In contrast, vaccine-induced protective immunity was found to be independent of both CD4 and CD8 T cells. Tracking studies demonstrated uptake of the Bp82 vaccine strain predominately by neutrophils in vaccine-draining lymph nodes and by smaller numbers of dendritic cells (DC) and monocytes. We concluded that protection following cutaneous immunization with a live attenuated Burkholderia vaccine strain was dependent primarily on generation of effective humoral immune responses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24101688      PMCID: PMC3837973          DOI: 10.1128/IAI.00915-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  61 in total

1.  A statistically defined endpoint titer determination method for immunoassays.

Authors:  A Frey; J Di Canzio; D Zurakowski
Journal:  J Immunol Methods       Date:  1998-12-01       Impact factor: 2.303

2.  Pseudomonas pseudomallei liver abscesses: a clinical, laboratory, and ultrasonographic study.

Authors:  T Vatcharapreechasakul; Y Suputtamongkol; D A Dance; W Chaowagul; N J White
Journal:  Clin Infect Dis       Date:  1992-02       Impact factor: 9.079

3.  Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis.

Authors:  Michelle Nelson; Joann L Prior; M Stephen Lever; Helen E Jones; Timothy P Atkins; Richard W Titball
Journal:  J Med Microbiol       Date:  2004-12       Impact factor: 2.472

4.  The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei.

Authors:  Mary N Burtnick; Paul J Brett; Sarah V Harding; Sarah A Ngugi; Wilson J Ribot; Narisara Chantratita; Angelo Scorpio; Timothy S Milne; Rachel E Dean; David L Fritz; Sharon J Peacock; Joanne L Prior; Timothy P Atkins; David Deshazer
Journal:  Infect Immun       Date:  2011-02-07       Impact factor: 3.441

5.  Burkholderia pseudomallei tropism and the melioidosis road map.

Authors:  W Joost Wiersinga; Tom van der Poll
Journal:  J Infect Dis       Date:  2009-06-15       Impact factor: 5.226

Review 6.  The molecular and cellular basis of pathogenesis in melioidosis: how does Burkholderia pseudomallei cause disease?

Authors:  Natalie R Lazar Adler; Brenda Govan; Meabh Cullinane; Marina Harper; Ben Adler; John D Boyce
Journal:  FEMS Microbiol Rev       Date:  2009-08-05       Impact factor: 16.408

7.  Speed of detection of Burkholderia pseudomallei in blood cultures and its correlation with the clinical outcome.

Authors:  C Tiangpitayakorn; S Songsivilai; N Piyasangthong; T Dharakul
Journal:  Am J Trop Med Hyg       Date:  1997-07       Impact factor: 2.345

8.  Isolation and characterization of Pseudomonas pseudomallei flagellin proteins.

Authors:  P J Brett; D C Mah; D E Woods
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

9.  A live experimental vaccine against Burkholderia pseudomallei elicits CD4+ T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins.

Authors:  Ashraful Haque; Karen Chu; Anna Easton; Mark P Stevens; Edouard E Galyov; Tim Atkins; Rick Titball; Gregory J Bancroft
Journal:  J Infect Dis       Date:  2006-09-25       Impact factor: 5.226

Review 10.  Development of Burkholderia mallei and pseudomallei vaccines.

Authors:  Ediane B Silva; Steven W Dow
Journal:  Front Cell Infect Microbiol       Date:  2013-03-11       Impact factor: 5.293

View more
  27 in total

Review 1.  Novel multi-component vaccine approaches for Burkholderia pseudomallei.

Authors:  L Morici; A G Torres; R W Titball
Journal:  Clin Exp Immunol       Date:  2019-04-08       Impact factor: 4.330

2.  Recent Advances in Burkholderia mallei and B. pseudomallei Research.

Authors:  Christopher L Hatcher; Laura A Muruato; Alfredo G Torres
Journal:  Curr Trop Med Rep       Date:  2015-06

Review 3.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

4.  Burkholderia mallei CLH001 Attenuated Vaccine Strain Is Immunogenic and Protects against Acute Respiratory Glanders.

Authors:  Christopher L Hatcher; Tiffany M Mott; Laura A Muruato; Elena Sbrana; Alfredo G Torres
Journal:  Infect Immun       Date:  2016-07-21       Impact factor: 3.441

5.  Antibodies against In Vivo-Expressed Antigens Are Sufficient To Protect against Lethal Aerosol Infection with Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Shawn M Zimmerman; Jeremy S Dyke; Tomislav P Jelesijevic; Frank Michel; Eric R Lafontaine; Robert J Hogan
Journal:  Infect Immun       Date:  2017-07-19       Impact factor: 3.441

6.  Burkholderia pseudomallei capsular polysaccharide conjugates provide protection against acute melioidosis.

Authors:  Andrew E Scott; Mary N Burtnick; Margaret G M Stokes; Adam O Whelan; E Diane Williamson; Timothy P Atkins; Joann L Prior; Paul J Brett
Journal:  Infect Immun       Date:  2014-05-27       Impact factor: 3.441

7.  A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis.

Authors:  Wildaliz Nieves; Hailey Petersen; Barbara M Judy; Carla A Blumentritt; Kasi Russell-Lodrigue; Chad J Roy; Alfredo G Torres; Lisa A Morici
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

8.  Prediction of Burkholderia pseudomallei DsbA substrates identifies potential virulence factors and vaccine targets.

Authors:  Ben Vezina; Guillaume A Petit; Jennifer L Martin; Maria A Halili
Journal:  PLoS One       Date:  2020-11-20       Impact factor: 3.240

9.  Use of Reverse Vaccinology in the Design and Construction of Nanoglycoconjugate Vaccines against Burkholderia pseudomallei.

Authors:  Laura A Muruato; Daniel Tapia; Christopher L Hatcher; Mridul Kalita; Paul J Brett; Anthony E Gregory; James E Samuel; Richard W Titball; Alfredo G Torres
Journal:  Clin Vaccine Immunol       Date:  2017-11-06

10.  Vaccines for the Prevention of Melioidosis and Glanders.

Authors:  Monica M Johnson; Kristy M Ainslie
Journal:  Curr Trop Med Rep       Date:  2017-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.